STERIS director exercises options, sells 1,481 shares
STERIS plc director Richard C. Breeden reported option exercises and share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
STERIS plc director Richard C. Breeden reported option exercises and share sales. On 2026-06-02, he exercised options to acquire 3,781 Ordinary Shares at $71.40 per share and sold 1,481 Ordinary Shares in an open-market transaction at a weighted average price of $209.51 per share.
Following these transactions, Breeden directly owned 38,964 Ordinary Shares. A separate entry shows 27,242 Ordinary Shares held indirectly, with footnotes explaining these are owned through Breeden-affiliated investment entities and that he may be deemed an indirect beneficial owner, while disclaiming beneficial ownership of 1,358 of those shares.
Insider Trade Summary
Exercise and sale activity reported; no spread calculated
Exercise and Sale
4 txns
Insider
Breeden Richard C
Role
Director
Sold
1,481 shs ($310K)
Approx. gross sale proceeds
$310K
Approx. exercise cost
$270K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Employee Stock Option (right to buy) | 3,781 | $0.00 | $0.00 |
| Exercise | Ordinary Shares | 3,781 | $71.40 | $270K |
| Sale | Ordinary Shares | 1,481 | $209.51 | $310K |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
Employee Stock Option (right to buy) — 0 contracts (Direct);
Ordinary Shares — 38,964 shares (Direct);
Ordinary Shares — 27,242 shares (Indirect, See Footnotes Below)
Footnotes (4)
- F1. Price reflects a weighted average sale price for multiple transactions ranging from $209.50 to $209.53 per share, inclusive. The Reporting Person undertakes to provide, upon request by the SEC Staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
- F2. Richard C. Breeden is the managing member of Breeden Capital Partners LLC, and managing member and chairman and chief executive officer of Breeden Capital Management LLC. Breeden Capital Partners LLC (the "General Partner") is in turn the general partner of Breeden Partners L.P. (the "Fund").
- F3. Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act of 1934, as amended, Mr. Breeden in his capacity as managing member, as well as chairman and chief executive officer of Breeden Capital Management LLC and as the managing member of Breeden Capital Partners LLC, may be deemed to be the indirect beneficial owner of the ordinary shares owned by the Fund and its General Partner, and may be deemed to have beneficial ownership of all such shares. Mr. Breeden disclaims beneficial ownership over 1,358 of these shares held by Breeden Partnership LLP.
- F4. This option to purchase 3,781 STERIS plc ordinary shares, which is fully vested, was received in connection with the redomiciliation of STERIS plc to Ireland in March 2019 in exchange for an option to purchase 3,781 ordinary shares for $71.40 per share in STERIS plc prior to the redomiciliation ("Old STERIS"), subject to the same terms and conditions as the original Old STERIS stock option.
Key Figures
Shares sold: 1,481 shares
Sale price (weighted average): $209.51 per share
Options exercised: 3,781 shares
+4 more
7 metrics
Shares sold
1,481 shares
Open-market sale of Ordinary Shares on June 2, 2026
Sale price (weighted average)
$209.51 per share
Multiple trades between $209.50 and $209.53
Options exercised
3,781 shares
Employee Stock Option exercise on June 2, 2026
Option exercise price
$71.40 per share
Conversion or exercise price for 3,781-share option
Direct holdings after transactions
38,964 shares
Ordinary Shares owned directly following June 2, 2026 trades
Indirect holdings
27,242 shares
Ordinary Shares held through Breeden-affiliated entities
Net buy/sell shares
-1,481 shares
Net effect of buy/sell activity in this Form 4
Key Terms
open-market sale, Employee Stock Option (right to buy), weighted average sale price, indirect beneficial owner, +1 more
5 terms
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Employee Stock Option (right to buy) financial
"security_title": "Employee Stock Option (right to buy)""
weighted average sale price financial
"Price reflects a weighted average sale price for multiple transactions"
indirect beneficial owner financial
"may be deemed to be the indirect beneficial owner of the ordinary shares"
Rule 16a-1(a)(2)(ii)(B) regulatory
"Pursuant to Rule 16a-1(a)(2)(ii)(B) of the Securities Exchange Act"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Richard C. Breeden report for STERIS (STE)?
Richard C. Breeden reported exercising options for 3,781 STERIS Ordinary Shares at $71.40 and selling 1,481 shares at a weighted average price of $209.51 on June 2, 2026. The filing also updates his direct and indirect share ownership totals.
What stock options did Richard C. Breeden exercise in the latest STERIS (STE) Form 4?
Breeden exercised an Employee Stock Option for 3,781 STERIS Ordinary Shares at a conversion or exercise price of $71.40 per share. The option, covering exactly 3,781 shares, became fully exercised, leaving zero remaining option shares after the June 2, 2026 transaction.
How are Richard C. Breeden’s indirect STERIS (STE) holdings structured?
Indirect holdings of 27,242 STERIS Ordinary Shares are attributed to Breeden Partners L.P. and its general partner Breeden Capital Partners LLC, managed by Breeden. Footnotes explain he may be deemed an indirect beneficial owner under Rule 16a-1(a)(2)(ii)(B), while disclaiming beneficial ownership of 1,358 of these shares.
AI-generated analysis. How Rhea-AI works. Not financial advice.
